FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
What happened
FDA reviewed the website https://www.fifty410.com in December 2025 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels showed 'Fifty 410' in a way that suggested Fifty 410 was the compounder, though it is not. FDA also said the claim 'clinically proven ingredients' falsely implied FDA approval or evaluation for safety and effectiveness.
What FDA found
FDA said the website's pictured labels identified 'Fifty 410' as if it were the compounder, but it is not.
FDCA §502(a) [21 U.S.C. §352(a)] and §502(bb) [21 U.S.C. §352(bb)]; 21 CFR §201.1(h)(2)FDA said the claim 'clinically proven ingredients' implies FDA approval or safety and effectiveness review that compounded drugs have not received.
FDCA §502(a) [21 U.S.C. §352(a)] and §502(bb) [21 U.S.C. §352(bb)]FDA said these misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA §301(a) [21 U.S.C. §331(a)]FDA also noted that receiving misbranded drugs in interstate commerce, or delivering them, is prohibited.
FDCA §301(c) [21 U.S.C. §331(c)]
What FDA wants
Within 15 working days, respond in writing to CDER's Office of Compounding Quality and Compliance with steps taken to correct the violations and prevent recurrence. Include the entities that produce the products, sample labeling, and how the website claims were addressed or removed.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies whose products are marketed by telehealth sites
- marketers making 'clinically proven' claims for compounded drugs
This is a summary. Read the original letter on fda.gov.